ImmunoMet Therapeutics to Present at the 11th Annual International BIO-Europe Spring Conference in Barcelona > Investors & Media

본문 바로가기


Investors & Media

ImmunoMet Therapeutics to Present at the 11th Annual International BIO-Europe Spring Conference in Barcelona

Date :
March 15, 2017

news_logo.png

 


ImmunoMet Therapeutics to Present at the 11th Annual

International BIO-Europe Spring Conference in Barcelona


Houston, TX, March 15, 2017 -- ImmunoMet Therapeutics, a development stage

biotechnology company focused on immuno-oncology and immune cell metabolism, today

announced that Benjamin R. Cowen, PhD, MBA, Chief Operating Officer, will present at the

11th annual International Bio-Europe Spring Conference on Wednesday March 22 at 9:45 am

at the CCIB Convention Center in Barcelona, Spain.

 

Dr. Cowen will provide an overview of ImmunoMet’s development pipeline. The Company’s

lead molecule, IM156, an OXPHOS inhibitor, has demonstrated positive in vivo results in

resistant brain and lung tumors in preclinical studies. ImmunoMet expects IM156 to enter a

Phase 1 clinical trial in the second quarter of 2017. Additionally, the Company’s second

program in immuno-oncology is being developed in combination with immunotherapies,

including an anti-PD1; it is in late stage lead-optimization and has demonstrated tumor

regression in a renal cancer model.

 

About ImmunoMet Therapeutics

ImmunoMet Therapeutics, a private, early stage biotechnology company, is dedicated to

developing innovative oncology products to improve the quality of life and make a

meaningful difference in the lives of cancer patients. The Company, a spinoff of HanAll, a

Korean biopharma company, is headquartered at JLABS in Houston. ImmunoMet’s R&D

program is focused on utilizing cellular metabolism to develop novel cancer and immuno-

oncology therapies, which include cancer metabolism designed to disrupt a tumor’s energy

source using OXPHOS inhibitors to treat drug resistant and relapse cancers and immuno-

oncology targeting immune suppressor cells to enhance the response of current

immunotherapies. On March 7, the Company announced the completion of its $5.0 million

Series B financing. For more information about the Company, please visit

www.immunomet.com

 

Contact

Benjamin R. Cowen: Chief Operating Officer, 215-527-1312, bcowen@immunomet.com

Joseph T. Schepers: Investor Relations, 770-558-5517, joeschepers@immunomet.com


Copyright © ImmunoMet. All rights reserved.